12:00 AM
Jan 22, 2001
 |  BioCentury  |  Tools & Techniques

Signal deal leads Celgene into SERMs

Selective estrogen receptor modulators (SERMs) were all the rage a few years ago, with their promise of harnessing the benefits of estrogen modulation without the side effects of broad activity. The reality has been less dramatic, as neither of the two marketed SERMs is perfect. Celgene Corp., which signed a deal with Novartis AG last week, believes its functional genomics platform for discovering SERMs...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >